Abstract
Protein kinase CK2 (formerly referred to as casein kinase II) is an evolutionary conserved, ubiquitous protein kinase. There are two paralog catalytic subunits, i.e. alpha (A1) and alpha (A2). The alpha and alpha subunits are linked to two beta subunits to produce a heterotetrameric structure. The catalytic alpha subunits are distantly related to the CMGC subfamily of kinases, such as the Cdk kinases. There are some peculiarities associated with protein kinase CK2, which are not found with most other protein kinases: (i) the enzyme is constitutively active, (ii) it can use ATP and GTP and (iii) it is found elevated in most tumors investigated and rapidly proliferating tissues. With the elucidation of the structure of the catalytic subunit, it was possible to explain why the enzyme is constitutively active [1] and why it can bind GTP [2]. Considerable information on the potential roles of CK2 in various disease processes including cancer has been gained in recent years, and the present review may help to further elucidate its aberrant role in many disease states. Its peculiar structural features [3-9] may be advantageous in designing tailor-made compounds with the possibility to specifically target this protein kinase [10]. Since not all the aspects of what has been published on CK2 can be covered in this review, we would like to recommend the following reviews; (i) for general information on CK2 [11-18] and (ii) with a focus on aberrant CK2 [19-22].
Keywords: Protein kinase, CK2, disease, cancer, protein phosphorylation, virus, inhibitors, inflammation
Current Medicinal Chemistry
Title: Protein Kinase CK2 in Human Diseases
Volume: 15 Issue: 19
Author(s): Barbara Guerra and Olaf-Georg Issinger
Affiliation:
Keywords: Protein kinase, CK2, disease, cancer, protein phosphorylation, virus, inhibitors, inflammation
Abstract: Protein kinase CK2 (formerly referred to as casein kinase II) is an evolutionary conserved, ubiquitous protein kinase. There are two paralog catalytic subunits, i.e. alpha (A1) and alpha (A2). The alpha and alpha subunits are linked to two beta subunits to produce a heterotetrameric structure. The catalytic alpha subunits are distantly related to the CMGC subfamily of kinases, such as the Cdk kinases. There are some peculiarities associated with protein kinase CK2, which are not found with most other protein kinases: (i) the enzyme is constitutively active, (ii) it can use ATP and GTP and (iii) it is found elevated in most tumors investigated and rapidly proliferating tissues. With the elucidation of the structure of the catalytic subunit, it was possible to explain why the enzyme is constitutively active [1] and why it can bind GTP [2]. Considerable information on the potential roles of CK2 in various disease processes including cancer has been gained in recent years, and the present review may help to further elucidate its aberrant role in many disease states. Its peculiar structural features [3-9] may be advantageous in designing tailor-made compounds with the possibility to specifically target this protein kinase [10]. Since not all the aspects of what has been published on CK2 can be covered in this review, we would like to recommend the following reviews; (i) for general information on CK2 [11-18] and (ii) with a focus on aberrant CK2 [19-22].
Export Options
About this article
Cite this article as:
Guerra Barbara and Issinger Olaf-Georg, Protein Kinase CK2 in Human Diseases, Current Medicinal Chemistry 2008; 15 (19) . https://dx.doi.org/10.2174/092986708785132933
| DOI https://dx.doi.org/10.2174/092986708785132933 |
Print ISSN 0929-8673 |
| Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Current concepts in the study of new therapeutic targets and the development of drugs for diseases of the central nervous system
Central nervous system (CNS) diseases are among the leading causes of chronic disability and mortality worldwide. According to the World Health Organization (WHO), neurological disorders affect over 1 billion people, and the cost of their treatment increases annually. However, advances in neuroscience and medicine are enabling fundamentally new approaches to ...read more
Sustainable Molecular Design for Health and Economy: New Directions in Medicinal Chemistry
The evolving landscape of medicinal chemistry is increasingly influenced by the urgent need to reconcile human health priorities with sustainability imperatives and economic feasibility. While drug discovery and therapeutic development pipelines lead to substantive scientific outcomes, they nonetheless remain disproportionately resource-intensive, environmentally taxing, and financially enclosed. In response to these ...read more
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Regulation of Angiotensin II Receptor Expression
Current Pharmaceutical Design RNA Interference and Neuromuscular Diseases: A Focus on Hereditary Transthyretin Amyloidosis
Current Gene Therapy Orthotopic Liver Transplantation in Alcoholic Liver Disease Patients
Reviews on Recent Clinical Trials The Role of Biologically Active Ingredients from Chinese Herbal Medicines in the Regulation of Autophagy in Treating Cardiovascular Diseases and Other Chronic Diseases
Current Pharmaceutical Design The Mechanism of Dead-in-Bed Syndrome and Other Sudden Unexplained Nocturnal Deaths
Current Diabetes Reviews Effect of Proteasome Inhibitors on the AAV-Mediated Transduction Efficiency in Retinal Bipolar Cells
Current Gene Therapy Salen Mn Complexes are Superoxide Dismutase/Catalase Mimetics that Protect the Mitochondria
Current Inorganic Chemistry (Discontinued) MCP-1/CCL2 as a Therapeutic Target in Myocardial Infarction and Ischemic Cardiomyopathy
Inflammation & Allergy - Drug Targets (Discontinued) Myocardial Energetics in Left Ventricular Hypertrophy
Current Cardiology Reviews Patent Selections:
Recent Patents on Inflammation & Allergy Drug Discovery Pharmacotherapy of Dilated Cardiomyopathy
Current Pharmaceutical Design Inflammation and Chronic Heart Failure: From Biomarkers to Novel Anti-inflammatory Therapeutic Strategies
Medicinal Chemistry Bradykinin Receptors in Ischemic Injury
Current Neurovascular Research Impact of N-acetylcysteine and Etodolac Treatment on Systolic and Diastolic Function in a Rat Model of Myocardial Steatosis Induced by High-Fat-Diet
Endocrine, Metabolic & Immune Disorders - Drug Targets Vitamin D and Vitamin D Receptor Activators in Treatment of Hypertension and Cardiovascular Disease
Cardiovascular & Hematological Disorders-Drug Targets 10 Years of SELDI: What Have we Learnt?
Current Proteomics The Role of Klotho Protein in Chronic Kidney Disease: Studies in Animals and Humans
Current Protein & Peptide Science Sacubitril/Valsartan: A New Dawn has Begun! A Revisited Review
Current Cardiology Reviews Contemporary Treatment of Amyloid Heart Disease
Current Pharmaceutical Design Prevalence of Dilated Cardiomyopathy in HIV-Infected African Patients Not Receiving HAART: A Multicenter, Observational, Prospective, Cohort Study in Rwanda
Current HIV Research





